Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) Receives Consensus “Hold” Recommendation From Analysts

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN – Get Rating) received a consensus recommendation of “Hold” by the nine research firms that cover the stock, Marketbeat.com reports. Four investment analysts rated the stock with a hold recommendation and three gave the company a buy recommendation. The 12-month average target price among brokerages that have reported on the stock over the past year is $154.14.

A number of brokerages have recently released reports on BHVN. HC Wainwright downgraded shares of Biohaven Pharmaceutical from a “buy” rating to a “neutral” rating in a Wednesday, May 11 report. Cantor Fitzgerald downgraded shares of Biohaven Pharmaceutical from an “overweight” rating to a “neutral” rating in a Wednesday, May 11 report. Morgan Stanley lowered its price target on shares of Biohaven Pharmaceutical from $148.00 to $146.00 and set an “equal weight” rating on the stock in a Wednesday, April 6 report. SVB Leerink downgraded shares of Biohaven Pharmaceutical from an “outperforming” rating to a “market performance” rating and set a target price of $150.00 for the stock. in a research note from Wednesday, May 11. Finally, Piper Sandler lowered her price target on Biohaven Pharmaceutical shares from $156.00 to $149.00 and gave the stock an “na” rating in a Tuesday, May 24 research note.

Biohaven pharmaceutical stock up 0.0%

NYSE BHVN opened at $146.02 on Thursday. The company has a market capitalization of $10.30 billion, a PE ratio of -12.33 and a beta of 1.10. Biohaven Pharmaceutical has a 52 week low of $79.01 and a 52 week high of $151.51. The company’s 50-day simple moving average is $144.25 and its two-hundred-day simple moving average is $128.28.

A d Tradewins

The safest option in the trades!

If you’re new to trading, you’ve probably heard the wrong word about options, that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering strategy, you will soon learn that the safest option for new accounts is the options themselves!

Biohaven Pharmaceutical (NYSE:BHVN – Get Rating) last reported quarterly results on Tuesday, May 10. The company reported ($2.97) earnings per share (EPS) for the quarter, missing analyst consensus estimates of ($2.52) by ($0.45). The company posted revenue of $318.85 million for the quarter, compared to $187.12 million expected by analysts. In the same quarter last year, the company posted ($4.21) earnings per share. As a group, equity research analysts expect Biohaven Pharmaceutical to post year-to-date EPS of -10.51.

Insider Trading at Biohaven Pharmaceutical

In other news, CAO George C. Clark sold 4,200 shares of the company in a trade that took place on Tuesday, May 10. The shares were sold at an average price of $141.50, for a total value of $594,300.00. As a result of the transaction, the chief accountant now owns 4,065 shares of the company, valued at $575,197.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, accessible via the SEC’s website. Insiders of the company own 12.40% of the shares of the company.

Institutional entries and exits

Several institutional investors and hedge funds have recently changed their positions in the company. Capital World Investors increased its holdings in Biohaven Pharmaceutical by 7.5% in the first quarter. Capital World Investors now owns 6,642,539 shares of the company valued at $787,606,000 after acquiring an additional 464,530 shares last quarter. BlackRock Inc. increased its position in Biohaven Pharmaceutical by 0.5% during the first quarter. BlackRock Inc. now owns 4,656,866 shares of the company valued at $552,163,000 after purchasing an additional 21,586 shares during the period. Stifel Financial Corp raised its position in Biohaven Pharmaceutical by 1.9% in the fourth quarter. Stifel Financial Corp now owns 3,049,995 shares of the company valued at $420,319,000 after purchasing an additional 55,650 shares during the period. Marshall Wace LLP increased its position in Biohaven Pharmaceutical by 3.0% during the fourth quarter. Marshall Wace LLP now owns 2,798,457 shares of the company valued at $385,657,000 after purchasing an additional 80,272 shares during the period. Finally, State Street Corp increased its position in Biohaven Pharmaceutical shares by 0.5% in the 1st quarter. State Street Corp now owns 1,655,834 shares of the company worth $196,332,000 after buying 8,140 more shares in the last quarter. Institutional investors hold 88.03% of the company’s shares.

Biohaven Pharmaceutical Company Profile

(Get a rating)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, is developing product candidates targeting neurological and neuropsychiatric diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as the development of Rimegepant for the preventive treatment of migraine; Zavegepant which is in Phase III clinical trials for the acute and preventive treatment of migraine, as well as for respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

See also

Analyst Recommendations for Biohaven Pharmaceutical (NYSE: BHVN)

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Biohaven Pharmaceutical right now?

Before you consider Biohaven Pharmaceutical, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Biohaven Pharmaceutical didn’t make the list.

While Biohaven Pharmaceutical currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here